Drug intelligence / Profile preview

CTA311

Development stage: Preclinical
Lead developer: Bioheng Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTA311 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19, developed by Nanjing Bioheng Biotech (Bioheng Therapeutics). It is being developed for the treatment of B-cell acute lymphoblastic leukemia (B-cell ALL) and non-Hodgkin lymphoma. As a CAR-T cell therapy, CTA311 involves genetically engineering a patient's own or donor T cells to express a receptor that specifically recognizes and binds to the CD19 antigen present on malignant B cells. This enables targeted immune-mediated destruction of cancerous B cells. The drug is currently in preclinical development[1][2][4].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CTA311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA311.

Explore the full profile